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Merkel cell carcinoma (MCC) is a rare neuroendocrine cancer of the skin that has a strong propensity to relapse and 
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(MCV) is detected in 70% to 80% of MCC tumors, but the significance of MCV infection is not yet understood. 
MicroRNAs (miRNA) have been reported to associate with many types of cancer, and miRNA profiles of other cancers 
with a virus etiology have been defined. The aim of this study was to compare the expression of five miRNAs, miR-
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according to MCV status using quantitative reverse transcription polymerase chain reaction (qRT-PCR).  
 
Materials and methods: 
 Sufficient RNA was extracted from 26 tumor samples and from control skin sample using the miRNeasy FFPE Kit 
(QIAGEN, Valencia, CA, USA). Reverse transcription of the RNA was done using the miScript II RT Kit (50) (QIAGEN). 
QRT-PCR was executed with miScript SYBR Green PCR Kit (QIAGEN).and LightCycler 480 instrument (Roche 
Diagnostics GmbH, Mannheim, Germany). Student’s t-test and Mann-Whitney U-test were used to evaluate 
differences in miRNA expression. 
  
Results: 
We found a statistically significant underexpression of mir-34a in MCV-negative tumors compared to MCV-positives. 
The other four miRNAs studied did not show significant expression differences according to MCV-status. There was 
no statistically significant difference in miRNA expression according to tumor location or metastasizing.  
 
Conclusion: 
The difference in miRNA expression according to MCV-status suggests distinct pathogenesis of the tumors. 
The role of underexpressed miR-34a in MCV-negative tumor pathogenesis remains unclear but it might be 
consequential in the tumorigenesis of MCV-negative tumors. 
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1 Introduction 
 
1.1 Merkel cell carcinoma 
 
Merkel cell carcinoma (MCC) is a rare neuroendocrine cancer of the skin that mainly 
affects the elderly population. It has a strong propensity to relapse and metastasize, 
both locally and systemically (1). The regional lymph nodes are a common site for 
metastasis. The cells of origin in MCC remain ambiguous (2). 
 
The diagnosis is based on histology combined with immunohistochemical studies. 
Cytokeratin-20 should stain positively and the thyroid transcription factor-1 negatively 
(3-5). There are three histological subtypes: the trabecular subtype, the intermediate 
subtype and the small cell type. (6,7) The intermediate subtype is the most universal, 
and together with the small cell type, they are the aggressive forms of the disease.  
 
1.2 Cells of origin 
 
MCC has been thought to rise from Merkel cells, cells of the basal layer of epidermis.  
Merkel cells are most abundant in areas of special sensory function, fingertips for 
example (8). They constitute Merkel cell-axon complexes with the primary nerve 
endings of the skin (9). Merkel cells have been proposed to rise from the neural crest 
(10,11) but their origin as well as their function still remains controversial (12). Merkel 
cells have been the primary candidate for cells of origin in MCC due to the appearance 
of neuroendocrine granules and cytokeratine-20 in MCC tumor cells (13,14). But their 
post mitotic state (15) and location in the epidermis oppose the fact that MCC tumors 
primarily reside in the dermis, and proliferative activity is frequently observed in MCC 
tumor cells (16,17). Epidermal stem cells are prospective cells of origin, but experimental 
evidence is yet to be reported (2). The etiology of the MCC has not been entirely solved, 
but exposure to ultraviolet radiation (18-20) and immunosuppression contribute to MCC 
(21-24).  
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1.3 Prognosis and treatment 
 
The five-year survival rate of MCC patients is around 70% (25-28), but involvement of 
the local lymph nodes and more distant metastases reduce the survival rates 
considerably (29,30). Sentinel lymph node biopsy (SLNB) has been shown to be an 
important tool to define the stage of MCC. A positive SLNB may predict the progression 
of local metastases (31). Tumor size < 2cm is a favorable prognostic factor (32). No 
treatment protocol has been accepted unanimously due to scarce patient material, but 
surgical excision and SNLB followed by radiation treatment to the local skin area is the 
common course of treatment (33). 
 
1.4 Merkel cell polyomavirus 
 
 In 2008, a new polyomavirus was detected in 80% of a compilation of MCC samples (34). 
The virus was named Merkel cell polyomavirus (MCV) and has ever since been reported 
in 70% to 80% of the MCCs explored (35-39). Immunocompromised patients have an 
even higher incidence of MCV in their tumors (40,41). Virus positive patients have a 
more preferable course of the disease (39), yet there are studies contradicting this 
conclusion (42,43). Therefore the significance of the MCV infection is not yet completely 
perceived.  
 
MCV DNA integrates clonally into the host cell genome (34) and undergoes truncating 
mutations in the MCV large T antigen (LT) helicase, which incapacitates the viral 
replication machinery (44). Li et al. showed that a truncating mutation of the MCV LT, 
which deletes the C-terminal p53 tumor suppressor activating region while retaining the 
N-terminal Retinoblastoma inhibiting domain, is likely to be a requirement for the 
infected cells to become tumorigenic (45). Clonal integration is evident in the primary 
tumors and in metastases as well, suggesting that the proliferation of tumor cells occur 
after the integration of the viral DNA (46,47).    
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1.5 MicroRNAs and cancer 
 
MicroRNAs (miRNA) are small non-coding RNA molecules of about 20-25 nucleotides. 
MiRNAs are known to have an important role in controlling cellular development, 
differentiation, proliferation and apoptosis. They participate in cellular processes by 
negatively regulating gene expression at the transcriptional or post-transcriptional level 
(48,49). In addition to DNA mutation, epigenetic mechanisms like DNA methylation and 
Histone modification regulate miRNA gene expression (50). Particularly methylation of 
the genomic sequences called CpG islands firmly represses the transcription of those 
regions, and many miRNA genes relate to these CpG islands (50). MiRNAs have been 
reported to associate with many types of cancer (51,52), for example chronic 
lymphocytic leukaemia, glioblastoma and breast cancer as well as cervical cancer, but 
the key miRNAs in MCC pathogenesis remain unidentified. In 2011, Lee et al. reported 
that the MCV genome encodes a viral miRNA that is involved in the virus’s escape from 
immunosurveillance (53).  
 
MiRNA profiling for other cancers with viral etiology has been done previously at least 
for the human papillomavirus (HPV) associated cervical cancer and the Epstein-Barr 
virus-associated NK/T-cell lymphomas (54,55). In 2013 Xie et al. evaluated miRNA 
expression profiles in MCC tumors according to the MCV status and found distinct 
expression profiles for MCV positive and negative tumors (56).  Our group, led by Sahi 
in 2013, used microarray techniques to compare microRNA expression between MCV 
positive and negative tumors. We found four miRNAs to be underexpressed in MCV 
negative tumors. These miRNAs were miR-34a, miR-30a, miR-1539 and miR-142-3p. The 
only miRNA overexpressed was miR-181d. 
 
1.6 Aim of the study 
The aim of this present study was to compare the expression of five miRNAs, miR-34a, 
miR-30a, miR-1539, miR-142-3p and miR-181d in MCC tumor samples according to MCV 
status, using a quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
and potentially validate these differences in miRNA regulation. The results were linked 
to patients’ clinical parameters and analyzed statistically. 
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2  Materials and Methods 
 
2.1  Tumor samples 
 
 
Data on patients diagnosed with MCC in Finland during 1979-2004 was obtained from 
the Finnish Cancer Registry and Helsinki University Hospital files. Clinical details, such as 
age at diagnosis, gender, tumor size and location as well as data of other diseases and 
metastasis were extracted from hospital records. Formalin-fixed, paraffin-embedded 
tissue blocks were accordingly retrieved from the pathology archives. The study was 
approved by the local ethics committee. 
 
The MCC diagnoses were confirmed in a blinded fashion during our earlier studies by 
two researchers with special expertise in MCC pathology (Tom Böhling and Heli Kukko). 
The samples were stained with hematoxylin and eosin, and we performed 
immunohistochemistry with antibodies for cytokeratin-20 (CK-20, DakoCytomation, 
Glostrup, Denmark) and thyroid transcription factor-1 (TTF-1; Novocastra, Balliol 
Business Park West, Benton Lane, Newcastle Upon Tyne, UK). We required for the 
histological diagnosis of MCC 1. that the morphology was compatible with MCC in light 
microscopy, 2. positive staining for CK-20 and 3. negative staining for TTF-1. 
 
 In our previous study, the presence of MCV DNA was analyzed from DNA extracted from 
representative deparaffinized tumor sections (39). Quantitation of MCV DNA was done 
using real-time PCR. The relative DNA sequence copy number for each tissue sample 
was expressed as a ratio of MCV DNA-to-protein tyrosine phosphatase gamma receptor 
gene (PTPRG) DNA. When the MCPyV DNA to PTPRG DNA ratio was >0 the sample was 
considered positive (39). 
 
For this study, 14 MCV-positive and 13 MCV-negative MCC tumors and one control 
sample from healthy skin were chosen based on the amount of paraffinized tumor 
sample available.  
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2.2  RNA extraction 
 
RNA was extracted from 27 tumor samples and from a control skin sample. Extraction 
was done using the miRNeasy FFPE Kit (QIAGEN, Valencia, CA, USA cat.no. 217504). For 
deparaffinization ,we used the Deparaffinization Solution (QIAGEN, cat.no. 19093).  
Extraction steps were: 
1. 160 µl Deparaffinization Solution was added to microcentrifuge tubes containing the tumor sample 
sections. Samples were vortexed for 10 seconds and centrifuged briefly.  
2. Samples were incubated at 56°C for 3 min, then allowed to cool to room temperature. 
3. 150µl of Buffer PKD was added, and the samples were mixed by vortexing and then centrifuged for 1 
min at 11,000 x g (10,000 rpm). 
4. 10µl of proteinase K was added to the lower, clear phase. Mixing was done gently by pipetting up and 
down.  
5. Samples were incubated at 56°C for 15 min, then at 80°C for 15 min. 
6. Lower, clear phase was transferred into a new microcentrifuge tube, and the samples were incubated 
on ice for 3 min. Then they were centrifuged for 15 min at 16,100 x g. 
7. The supernatant was transferred to a new microcentrifuge tube without disturbing the pellet.  
8. 16µl DNAse Booster Buffer and 10µl DNase I stock solution was added. The tubes were mixed by 
inverting and centrifuged briefly. Samples were incubated at room temperature for 15 min.  
9. 320µl of Buffer RBC was added and mixed thoroughly by pipetting. We added 1120µl of ethanol 
(100%) and after mixing by pipetting, 700µl of sample was transferred to an RNeasy MinElute spin 
column placed in a 2 ml collection tube. Samples were centrifuged for 15 s at 11,000 x g and the flow-
through was discarded. This was repeated until the entire sample had passed through the spin column. 
10. 500µl of Buffer RPE was added to the spin columns and they were centrifuged for 15 s at 11,000 x g. 
The flow-through was discarded. Again 500µl of Buffer RPE was added, and the samples were 
centrifuged for 2 min at 11,000 x g, after which the collection tubes were discarded with the flow-
through.  
11. The spin columns were placed in new collection tubes. Tubes were centrifuged at full speed (16,100 x 
g) for 5 min with the lids of the columns open. Collection tubes were discarded with the flow-through. 
12. Spin columns were placed into new microcentrifuge tubes, and 20µl of RNase-free water was added 
directly to the spin column membranes. Tubes were centrifuged for 1 min at full speed. The result was 
RNA elution of about 18µl per sample.   
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The NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, 
USA) was used for quantification of RNA. One MCV-negative tumor sample was excluded 
from the study because of insufficient RNA concentration. RNA was stored in a -70°C 
freezer until the Reverse transcription to cDNA was commenced. 
 
2.3  Quantitative Reverse Transcription PCR 
 
Reverse transcription of the RNA was done using the miScript II RT Kit (50) (QIAGEN 
cat.no. 218161). Each tumor RNA sample was diluted to a concentration of 300ng/µl, 
and 1µl of dilution was added to the Reverse transcription reaction components, which 
included: 4µl miScript HiSpec Buffer, 2µl miScript Nucleics Mix, 11µl RNase-free water. 
The control RNA sample was diluted to 500ng/µl, and 1µl of the dilution was added to 
reverse transcription reaction components.  
Samples were first incubated for 60 min at 37°C, then for 5 min at 95°C to inactivate the 
reverse transcriptase mix.  Afterwards the samples were placed on ice, and 5µl of each 
sample was transferred to new tubes and mixed with 10µl of RNase-free water. This 
resulted with cDNA aliquots with a concentration of 5ng/µl. In addition, the cDNA 
derived from the control skin sample was diluted with RNase-free water to produce an 
aliquot with concentration of 5ng/µl. The cDNA was stored in a -20°C freezer until the 
PCR was started.  
Quantitative RT-PCR was executed with miScript SYBR Green PCR Kit (QIAGEN cat.no. 
2180739) and LightCycler 480 instrument (Roche Diagnostics GmbH, Mannheim, 
Germany). 5ng of cDNA was mixed in PCR plate with the reaction components, including 
10µl SYBR Green PCR mix, 2µl Universal Primer, 2µl primer for the miRNA desired to be 
amplified and 5µl RNase-free water. Each sample was transferred to a LightCycler 
capillary and placed into the LightCycler. PCR cycling conditions consisted of an initial 
activation step at 95°C for 15 minutes followed by 50 cycles with denaturation at 94°C 
for 15 seconds, annealing at 55°C for 30 seconds and extension at 70°C for 30 seconds.  
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PCR was performed on all of the samples with 6 different primers. The primers for the 
amplification of miRNAs: mir-34a, mir-30a, mir-181d, miR-142-3p, mir-1539 and the 
small nuclear RNA (snRNA) U6 were purchased from QIAGEN. U6 expression was used 
as a reference in statistical analysis. U6 is well suited for this purpose due to its high 
conservation throughout the evolution of many species. 
Every PCR run consisted of a certain number of tumor samples as well as the skin control 
sample, which acted as a calibrator of the miRNA expression in statistical analysis, and 
negative control sample, RNase-free water, which was used to observe possible 
contamination. Each tumor sample and the control sample had a replica on the PCR 
plate to increase the accuracy of the experiment. Melting curve analysis was also 
performed to check for nonspecific amplification. 
 
2.4  Statistical Analysis 
 
Ct values (threshold cycle) for every sample and its replica were collected to a Microsoft 
Office Excel file from the LightCycler software, and the mean Ct value was calculated for 
each sample. We used the ΔΔCt method for the relative quantification of miRNA 
expression. The equation used: ΔΔCt = (CtmiRNA – CtU6)control skin – (CtmiRNA – CtU6)tumor sample 
 
The relative quantity (RQ) for each miRNA, compared with the quantity of U6 was 
calculated using equation 2-ΔΔCt. Mean and median RQs for MCV-positive and MCV-
negative tumors were calculated for every miRNA. The student’s t-test was used to 
evaluate statistically significant differences in miRNA expression between the two 
groups: the MCV-negative tumors and MCV-positive tumors. MiRNA expression 
according to MCV-status was confirmed with the Mann-Whitney U-test using the 
median RQs. In addition to comparison according to MCV-status, tumors were divided 
into subgroups based on metastasis and location on sun exposed versus non-exposed 
areas (Figure 1.). The Mann-Whitney U-test was used to compare miRNA expression in 
these groups (location, metastasis). P-values of less than 0.05 were considered 
statistically significant.  
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3  Results 
 
This study comprised 26 MCC patients, with 18 (69%) females and a mean age of 78.  
The mean tumor size was 3cm, ranging from 1cm to 8.5cm. Tumors were most 
commonly located in the head and neck 12 (46%) or limbs, and only five (20%) tumors 
were located in the trunk.  
12 patients (46%) had previous chronic diseases, including cancers, for example breast 
or prostate cancer, and coronary disease.  Three patients had immunocompromising 
diseases such as psoriasis and diabetes, and one patient was immunosuppressed 
following a kidney transplant. Nine (35%) patients developed local or distant metastasis 
during the course of disease. Six (23%) patients (patients number 2, 7, 8, 9, 11 and 17) 
were alive five years after the MCC diagnosis. 
14 of the tumors were MCV-positive and 12 MCV-negative. 9 (75%) of the MCV-negative 
tumors were located in the head and neck area or limbs. Tumor locations are illustrated 
in Figure 1, and detailed clinical data are presented in Table 3. 
The male patients’ tumors had mean RQs of 1.49 for miR-34a, 2.30 for miR-30a, 1.61 for 
miR-142-3p, 0.67 for miR-181d and 5.46 for miR-1539. For the females, the 
corresponding values were 0.85, 2.14, 1.27, 0.30 and 1.30. Patients under 78 years had 
mean RQs of 1.03, 2.14, 1.80, 0.57 and 5.16. For the patients 78-years-old or older, the 
values were 1.06, 2.22, 1.15, 0.33 and 1.21.  
MiR-34a, miR-30a, miR-1539, miR-142-3p were downregulated in MCV negative tumors 
compared with MCV positive tumors. Yet, only mir-34a expression reached statistical 
significance (p=0.0063). MiR-181d was slightly up- or downregulated depending on 
which were used in comparison, the median or mean RQ values. Detailed results of the 
PCR are presented in Tables 1 and 2. There was no statistical significant difference in 
miRNA expression according to tumor location or metastasis. 
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Table 1. 
 MCV positive1  MCV negative1 p-value2 expression(neg. vs pos.) 
miR-34a 1.53 0.49 0.0063 underexpressed 
miR-30a 2.39 1.96 0.41 underexpressed 
miR-1539 3.53 1.47 0.32 underexpressed 
miR-142-3p 1.89 0.77 0.081 underexpressed 
miR-181d 0.42 0.40 0.91 underexpressed 
1 Mean Relative quantity (RQ) values calculated using the equation 2-ΔΔCt. 
2 Calculated using Student’s t-test 
  
 
 
 
Table 2. 
 
 MCV positive3  MCV negative3 p-value4 expression(neg. vs pos.) 
miR-34a 1.16 0.23 0.0043 underexpressed 
miR-30a 1.80 1.56 0.49 underexpressed 
miR-1539 1.17 0.66 0.17 underexpressed 
miR-142-3p 1.29 0.56 0.11 underexpressed 
miR-181d 0.26 0.38 1.00 overexpressed 
3 Median Relative quantity (RQ) values using the equation 2-ΔΔCt. 
4 Calculated using Mann-Whitney U-test 
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Table 3.  
 
Patient Sex             Age at 
diagnosis  
 MCV 
status 
Tumor 
size (mm) 
Tumor 
location        
    Preceding 
    Diseases 
  Metastasis  
  location 
 
1 F   90 negative   20 
 
Right 
Temple  
       Right 
  neck/chin                                   
 
2 M   68 positive    Right 
cheek 
    Coronary   
    disease 
  Scalp  
3 F   80 positive   85 Back of 
the thigh 
       axillar and 
  inguinal  
  lymph nodes 
 
4 M   59 positive   70 Chest    
5 M   67 negative   15 Left cheek      Kidney     
     transplant                     
   
 
 
6 F   72 positive   12 left knee      Parkinson’s 
     disease 
  
7 F   81 positive   20 Right 
cheek 
        
8 F   83 negative   50 Right arm    
9 F   85 negative    15 Left 
temple 
   
10 F   91 positive   30 forehead    
11 M   71 positive   34 Right 
buttock 
   
12 F   95 positive   18 left cheek    
13 F   87 positive   30 Left 
shoulder 
      Coronary    
      disease 
   axillar  
   lymph node,   
   right thigh 
 
14 F   77 negative   20 Right 
cheek 
      Diabetes.   
      Coronary 
      disease 
 Mediastinum.  
   pleura and  
   frontal lobe 
 
15 F   79 negative   20 Right 
breast 
      Breast 
      cancer 
  
16 F   72 negative   13 Calf           inguinal  
   lymph nodes     
 
17 F   57 positive   33 Right 
cheek 
   
18 M   78 negative   25 Neck       Psoriasis.  
      solar  
      keratosis 
    Anal canal. 
    pancreas 
 
19 M   79 positive   40 Left 
forearm 
        
20 F   81 negative    Left upper 
back 
      Coronary 
      disease.  
      osteoporosis 
  
21 F   84 positive   24 Right 
shoulder 
      Diabetes   
22 M   82 negative   28 Neck       Prostate  
      cancer.           
      solar keratosis 
  
23 M   85 positive   75 Left arm       non-Hodking  
      lymphoma 
   axillar lymph   
   nodes        
 
24 F   84 negative   15 Back       Breast  
      cancer 
  
25 F   87 positive   20 Cheek    
26 F   60 negative   10 Left arm       Heart. lung  
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Figure 1.  
 
 
 
 
 
Tumors in the head and neck region and the tumor in the left forearm were considered to be  
located in a sun-exposed area. 
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4  Discussion 
 
In this study, the expression profiles of five microRNAs (miR-34a, miR-1539, miR-30a, 
miR-142-3p and miR-181d) were compared according to the MCV status of the MCC 
tumors using quantitative RT-PCR. In consensus with our previously obtained microarray 
results, we confirmed statistically significant underexpression of miR-34a in MCV-
negative tumor samples compared with MCV-positive tumors (p=0.0063).  
MiR-34a overexpression in MCV-positive versus MCV-negative MCC was first reported 
by Xie et al (2013) (56). Similar to us, they first used microarray analysis to define global 
miRNA profiles of MCC tumors according to MCV-status and then used qRT-PCR for 
validation of the most significant expression differences. In both studies, microarray 
analysis yielded miR-34a and miR-30a overexpression in MCV-positive tumors. 
Otherwise, the miRNAs selected for the qRT-PCR validation in this current study were 
different; Xie et al. confirmed significant overexpression of miR-375, miR-769-5p and 
underexpression of miR-203 in MCV-positive tumors (56). Based on these findings, it is 
reasonable to propose that there might be a deviation in miRNA profiles regardless of 
MCV-status. However, since both of these independent studies found miR-34a to be 
differently expressed according to MCV status, it is possible that there are few key 
miRNAs whose dysregulation is consequential in MCC. In this study, the mean miR-142-
3p relative quantity was over 2.5-times higher in MCV-positive tumors compared with 
MCV-negatives, and this finding almost reached a statistical significance.  
Rodig et al. 2012 stated that all MCC tumors could actually contain MCV DNA (58). They 
used antibodies for the MCV Large T antigen to detect LTA in 97% of the tumor samples 
tested and also found MCV DNA in every 60 tumors tested with PCR analysis using a 
broadened set of MCV DNA specific primers. However, differences in miRNA expression 
suggest that there in fact are MCV-negative tumors whose pathophysiology may deviate 
to some extent from that of MCV-positives’. DNA methylation, Histone modification and 
mutations modify miRNA expression, and MCV viral proteins could potentially interfere 
with these modifications. Furthermore, dysregulation of miRNAs can lead to alterations 
in cell proliferation or initiation of apoptosis through abnormal gene expression.  
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 MiR-34a has p53 dependent tumor suppressor properties (59,60). It forms a positive 
feedback loop with p53 as the activation of p53 by miR-34a increases the production of 
miR-34a. This leads to further suppression of miR-34a target genes, one of which is the 
SIRT1 gene. SIRT1, an enzyme of the sirtuin protein family, deacetylates p53 abolishing 
the tumor suppressive effects of p53. MiR-34a tumor suppressor properties, therefore, 
are at least partly explained by blocking SIRT1 (60,61). Sihto et al. reported that in MCC 
p53 expression is associated with TP53 gene mutations, which are observed by 
immunohistochemistry only in MCV LTA negative MCC tumors. This suggests that p53 
could be involved in the tumorigenesis of MCV-negative tumors (62). They found p53 
expression infrequently in MCV LTA positive tumors, and lower copy numbers of the 
MCV DNA were observed in p53-positive tumors compared with p53-negatives (62). The 
underexpression of miR-34a in MCV-negative tumors might have oncogenic effects. 
Another transcription factor that regulates miR-34a is c-Myc. Unlike p53, c-Myc 
suppresses miR-34a expression (63). Sotillo et al. (2011) reported that miR-34a 
enhances cell survival by reducing p53 levels in c-Myc overexpressed Burkitt’s 
lymphoma (BL) cell lines in the presence of chemotherapy (64). They suggested that 
miR-34a could have implications for other tumors with c-Myc deregulation and that miR-
34a could be considered as a therapeutical target in such malignancies (64). One study 
reported that 70% of the tested MCC samples expressed c-Myc (65). Although c-Myc 
expression was not correlated with MCV-status (65), miR-34a could have a connection 
with c-Myc also in MCC, if even a slight miR-34a expression could interfere with c-Myc. 
Further, in MCV-positive tumors, miR-34a could lower p53 expression via c-Myc more 
efficiently due to overexpression of miR-34a. Moreover, this could potentially promote 
drug resistance as in BL cell lines (64).  
Sahi et al. (2012) reported that the expression of anti-apoptotic protein bcl-2 indicates 
better prognosis of MCC patients (66). Mir-34a is a negative regulator of bcl-2 (67), and 
overexpression of miR-34a has been reported to inhibit bcl-2 in hepatocellular 
carcinoma (68). Since bcl-2 expression is a positive prognostic factor in MCC, the 
function of miR-34a in MCC might not be tumor suppressive if its overexpression inhibits 
bcl-2. This also suggests that the MCV-tumor positive patients reported preferable 
course of the disease could not be explained solely with miR-34a overexpression (39).  
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T lymphocyte infiltration within the tumor tissue and strong T cell infiltration indicates 
a better prognosis in MCC (69,70). Interestingly, Shin et al. reported that miR-34a 
increases T cell activation (71). Could there be a connection between MCV-positive 
tumors, overexpression of miR-34a and preferable course of the disease due to 
enhanced activation of T cells? However, this would require that miR-34a was also 
overexpressed in the infiltrating T cells.  
Prominent miR-34a reduction in HPV induced cervical cancer was reported by Wang et 
al. They showed that a viral oncoprotein E6 reduces miR-34a expression by destabilizing 
p53, which enables cells to proliferate (72). miR-34a was also suggested to have 
unknown p53-independent activation mechanisms (72).  In contrast, we showed that 
MCC tumors with MCV infection are associated with greater expression of miR-34a than 
MCV negative tumors. This inspires one to ask, does MCV infection affect miR-34a 
expression in MCC and if its action is to upregulate miR-34a, does the dysregulation of 
this miRNA impact the progression of this cancer. 
Patients whose tumors were included in the study presented with several features 
typical for MCC. The age distribution was normal for MCC and the majority (80%) of the 
tumors were located in the head and neck region or limbs. In the highest UV-radiation 
exposed area, the head and neck region, there were 12 tumors (46%), which reminds 
that UV-radiation has an eminent causation to MCC. On the contrary, the five-year 
survival rate in this study was much lower than the rate usually reported (25-28). This 
could be partly explained by previous diseases that 46% of the patients had, but also by 
the fact that nine patients’ cancers progressed to a metastasized state. We did not find 
a correlation between miRNA expressions and location of the tumor or progression of 
metastasis. Nevertheless, it would not be overly surprising should further studies show 
such correlations. Quite interesting was that mir34a RQ value was 5- to 19-times greater 
in tumor from the only patient who progressed to metastatic disease compared with 
other six tumors taken from those patients that survived more than 5 years.  
The limitations of this study are the small sample size and scarce tumor material; then 
again there are not much more extensive tumor series anywhere due to the rareness of 
this cancer. Strengths of the present study are that the qRT-PCR yielded results 
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consistent with the microarray analysis and that the statistical analysis was done with 
two different methods, the student’s t-test and the Mann-Whitney U-test.  
Possible future directions would be to compare the expression of bcl-2 and miRNAs, 
especially miR-34a, in MCC tumors and to further compare the expression of miRNAs in 
primary tumors and their metastases and also the adjacent non-tumorous skin in order 
to find out the extent of miRNA dysregulation. An additional approach would be 
examine MCC tumors for T cell infiltration and compare to miRNA expression and 
survival of patients.  
In conclusion, we found significant underexpression of miR-34a in MCV-negative 
tumors. In addition, miR-30a, miR-1539 and miR-142-3p were underexpressed in MCV-
negative tumors compared to MCV-positives, but these findings failed to reach 
statistical significance. These results suggest that MCV-positive tumorigenesis 
potentially diverges from the MCV-negatives’. Essentially the underexpression of miR-
34a might be consequential in the tumorigenesis of MCV-negative tumors.  
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